Although ICIs have shown excellent efficacy in NSCLC, their efficacy varies widely, only a subset of patients, especially those with high PD-L1 expression, benefit from long-term responses, and a large proportion of patients do not show obvious curative effect or drug resistance. The gene discussed is CD274; the disease is non-small cell lung carcinoma.